Roberto Licchetta

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.

A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.

Journal: BMC cancer
Published: August 22, 2018

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

Journal: Oncotarget
Published: July 08, 2017

Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia.

Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia.

Journal: Advances in biological regulation
Published: April 29, 2017

Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite.

Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite.

Journal: Oxidative medicine and cellular longevity
Published: March 09, 2017

Tramesan, a novel polysaccharide from Trametes versicolor. Structural characterization and biological effects.

Tramesan, a novel polysaccharide from Trametes versicolor. Structural characterization and biological effects.

Journal: PloS one
Published: October 21, 2016

Erratum: The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.

Erratum: The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.

Journal: Scientific reports
Published: February 06, 2016

The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.

The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.

Journal: Scientific reports
Published: July 30, 2015

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.

Journal: Oncotarget
Published: April 09, 2015

The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling.

The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling.

Journal: Experimental hematology
Published: January 21, 2015

Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias.

Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias.

Journal: Blood
Published: December 16, 2014
Showing 1-10 of 10

Last Updated: 09/26/2026